November 17, 2022
FDA: Class I recall of Insulet Omnipod DASH PDM
Editor's Note
The Food and Drug Administration (FDA) on November 16 identified the recall by Insulet of its Omnipod DASH Insulin Management System Personal Diabetes Manager (PDM) as Class I, the most serious.
The recall was initiated because of PDM battery issues, including:
- Battery swelling
- Fluid leakage from the battery
- Extreme overheating that may pose a fire hazard.
The company reports 455 complaints, three fires, and no injuries or deaths.
Distribution dates were July 27, 2018, to August 31, 2022.
Free Daily News
- GLP-1 agonists linked to food retention in EGD, but not combined EGD-colonoscopy
- Healthcare employment up in September
- World's first all-plastic ankle replacement offers hope for patients with metal allergies
- AAMI, CTA partners to develop healthcare AI standards
- ECRI issues guidance to address medical supply shortages caused by Hurricane Helene, dockworkers’ strike
- FDA designates Class 1 recall for IPV therapy system
- Study: Early detection of atherosclerosis linked to lower mortality risk
- Repeal of CON laws for ASCs expands healthcare access, number of facilities in rural areas
- Spatial computing trial shows promise for enhancing OR efficiency, reducing strain on surgeons
- Vice presidential debate highlights healthcare, abortion policy differences
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement